Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Elucidating m6A RNA modification and its impact in breast cancer

EF 2022-23

Résumé
Breast cancer diagnoses and deaths are continuously rising, thus the identification of targets for treatment is necessary to alter the trajectory for diagnosed women. Although the vast number of mutations present in cancer makes it increasingly difficult to find targets for therapeutics, improving our knowledge of diseases at an epitranscriptome level would greatly extend our list of candidates. It has been identified that N6-methyladenosine (m6A) is the most common modification found on RNA transcripts and has various roles in breast cancer progression, making it and its’ interactors of interest for this study. One of these is METTL14 which binds METTL3, activating the m6A writer complex. METTL14 then binds the complex to the target RNAs for m6A ‘writing’. Previous work in the Schramek Lab has demonstrated that targeting Mettl14 via lentiviral sgRNAs led to significant acceleration in tumorigenesis in mice. This suggests that Mettl14 normally acts as a tumor suppressor and that dysregulation of m6A modifications in the transcriptome can induce breast cancer. I aim to understand the function of Mettl14 in breast cancer formation by analyzing whether METTL14’s role in cancer is RNA methylation-dependent or -independent. If the tumor suppressive effect of Mettl14 is methylation-dependent, I hypothesize that other members of the m6A modification pathway should have tumor suppressive or oncogenic functions. CRISPR technology will be applied to target these members for identifying whether they are tumor suppressors or oncogenes. Understanding how each m6A writer and eraser contributes to dysregulation of m6A methylation in breast cancer can potentially lead to new treatment targets in basal-like breast cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486099
Name
Sanayhie Samantha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating m6A RNA modification and its impact in breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Crispr Gene Editing; Epitranscriptomics; M6a Modification
Abstract
Breast cancer diagnoses and deaths are continuously rising, thus the identification of targets for treatment is necessary to alter the trajectory for diagnosed women. Although the vast number of mutations present in cancer makes it increasingly difficult to find targets for therapeutics, improving our knowledge of diseases at an epitranscriptome level would greatly extend our list of candidates. It has been identified that N6-methyladenosine (m6A) is the most common modification found on RNA transcripts and has various roles in breast cancer progression, making it and its’ interactors of interest for this study. One of these is METTL14 which binds METTL3, activating the m6A writer complex. METTL14 then binds the complex to the target RNAs for m6A ‘writing’. Previous work in the Schramek Lab has demonstrated that targeting Mettl14 via lentiviral sgRNAs led to significant acceleration in tumorigenesis in mice. This suggests that Mettl14 normally acts as a tumor suppressor and that dysregulation of m6A modifications in the transcriptome can induce breast cancer. I aim to understand the function of Mettl14 in breast cancer formation by analyzing whether METTL14’s role in cancer is RNA methylation-dependent or -independent. If the tumor suppressive effect of Mettl14 is methylation-dependent, I hypothesize that other members of the m6A modification pathway should have tumor suppressive or oncogenic functions. CRISPR technology will be applied to target these members for identifying whether they are tumor suppressors or oncogenes. Understanding how each m6A writer and eraser contributes to dysregulation of m6A methylation in breast cancer can potentially lead to new treatment targets in basal-like breast cancer.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sanayhie, Samantha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~